Biologics/Biosimilars/Step Therapy/Updates
Introduced
Moved
Reached a final decision
Became law
Derived from the official record below.
Officially: “AN ACT TO AMEND TITLE 18 OF THE DELAWARE CODE RELATING TO THE STEP THERAPY EXCEPTION PROCESS.” Read the full text
153rd General Assembly
What it does
This Act modernizes Delaware law by adding modern medical treatment options biologics or biosimilars to the step therapy exception process. The current law was passed before biosimilars were widely available. Biosimilars are to biologics what generic drugs are to traditional drugs once their exclusivity expires. This revision adds an exclusion to step therapy protocol exceptions for interchangeable biologics and biosimilars.
From the official legislative record, shown verbatim. Not legal advice.
Where it is
Introduced · May 19, 2026
Signed · Jul 28, 2026
Latest official status shown, exactly as the official record states it. The step by step history lives on the official page linked below.
The numbers
1
sponsor on the bill
Sponsors
Recorded votes
Recorded voteSenate · 2026-06-24 · Passed · Yes 21, No 0, NotVoting 0, Conflict 0, Absent 0, Vacant 0
Recorded voteHouse · 2026-06-11 · Passed · Yes 38, No 1, NotVoting 0, Conflict 0, Absent 2, Vacant 0
Roll-call results shown verbatim from the Delaware legislature’s records. A result reflects that roll call’s own motion, not the bill’s overall outcome.
Every fact on this page links to its source, starting with the official bill record. Last action: Signed (Jul 28, 2026).